ACXP vs. LLY
Compare and contrast key facts about Acurx Pharmaceuticals, Inc. (ACXP) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ACXP or LLY.
Key characteristics
| ACXP | LLY | |
|---|---|---|
| YTD Return | -42.56% | 34.23% |
| 1Y Return | -25.42% | 94.09% |
| Sharpe Ratio | -0.22 | 3.30 |
| Daily Std Dev | 118.97% | 30.00% |
| Max Drawdown | -83.78% | -68.27% |
| Current Drawdown | -72.12% | -1.41% |
Fundamentals
| ACXP | LLY | |
|---|---|---|
| Market Cap | $32.62M | $697.40B |
| EPS | -$1.15 | $5.79 |
| Revenue (TTM) | $0.00 | $34.12B |
| Gross Profit (TTM) | $0.00 | $21.91B |
Correlation
The correlation between ACXP and LLY is -0.00. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.
Performance
ACXP vs. LLY - Performance Comparison
In the year-to-date period, ACXP achieves a -42.56% return, which is significantly lower than LLY's 34.23% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ACXP vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Acurx Pharmaceuticals, Inc. (ACXP) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
ACXP vs. LLY - Dividend Comparison
ACXP has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.60%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACXP Acurx Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.60% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% | 2.84% | 3.84% |
Drawdowns
ACXP vs. LLY - Drawdown Comparison
The maximum ACXP drawdown since its inception was -83.78%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for ACXP and LLY. For additional features, visit the drawdowns tool.
Volatility
ACXP vs. LLY - Volatility Comparison
Acurx Pharmaceuticals, Inc. (ACXP) has a higher volatility of 25.93% compared to Eli Lilly and Company (LLY) at 8.49%. This indicates that ACXP's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
ACXP vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Acurx Pharmaceuticals, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities